Ampio Pharmaceuticals, Inc. AMPE

AMPE Company Overview

Ampio Pharmaceuticals, Inc. was a U.S.-based biopharmaceutical company focused on developing immunomodulatory and anti-inflammatory therapies for inflammatory conditions and respiratory diseases. The company historically operated in the biotechnology and specialty pharmaceutical sectors, with research efforts centered on compounds intended to reduce inflammation while limiting side effects commonly associated with corticosteroids and other systemic therapies. Its primary development candidate was Ampion, a biologic derived from human serum albumin that was investigated primarily for osteoarthritis of the knee and certain inflammatory indications.

The company’s business model relied largely on clinical-stage drug development rather than commercialized product sales, meaning its historical revenue base was primarily tied to financing activities rather than recurring pharmaceutical product revenue. Ampio positioned itself around the potential therapeutic application of low-molecular-weight fractions derived from albumin-based compounds and sought differentiation through anti-inflammatory mechanisms that it claimed could address unmet medical needs in musculoskeletal and pulmonary disease categories. Public filings and market disclosures indicate the company experienced substantial operational and financial challenges following mixed clinical outcomes and regulatory setbacks. Data regarding ongoing active operations after its restructuring and market delisting is inconclusive based on available public sources.